The Food and Drug Administration (FDA) of the United States has granted approval for Veklury (remdesivir), a covid-19 drug developed by Gilead for the purpose of treating the infants and children over the age period of 28 days. The decision of the US FDA has been making the drug the very first approved corona virus treatment for the children less than 12 years of age.
As a result of the approval action, the agency has also revoked the emergency use authorization for the drug that has been previously covering this pediatric population. In the past, the Veklury drug had been previously approved for the purpose of treating certain adults and patients with the novel corona virus.
Patrizia Cavazzoni, director of the Center for Drug Evaluation and Research of US FDA said, as the novel corona virus can cause serious illness in the children, and some of whom does not currently have an option of covid-19 vaccination and there continues for being a need for having safe and effective corona virus treatment options for the young kids.
She also said that, this approval of the first corona virus therapeutic for the young kids has been demonstrating the commitment of the US FDA to that need. The Veklury drug has not been a substitute for the corona virus vaccination in the individual for whom the novel corona virus vaccination and booster doses have been recommended. The US FDA has also approved two more vaccine for the prevention of the disease.
